Intellia Tops Revenue Estimates

Motley Fool11-08

Reported EPS of -$1.34 beat estimates of -$1.39. Revenue reached $9.1 million, surpassing the $8.28 million analyst estimate. Lead candidates NTLA-2001 and NTLA-2002 achieved significant...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481915612?lang=en_US&edition=fundamental","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fcdn.content.foolcdn.com%2Fimages%2F1umn9qeh%2Fproduction%2Ff9e7d5f633be79b4ec54a7c055896a8bd6600a6e-600x400.jpg&op=resize&w=165&h=104","is_english":true,"pubTime":"2024-11-08 03:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481915612","market":"us","top_or_hot":-1,"title":"Intellia Tops Revenue Estimates","media":"Motley Fool","content":"<div>\n<p>Reported EPS of -$1.34 beat estimates of -$1.39.\n\n\n\n\n\n\n\nRevenue reached $9.1 million, surpassing the $8.28 million analyst estimate.\n\n\n\n\n\n\n\nLead candidates NTLA-2001 and NTLA-2002 achieved significant...</p>\n\n<a href=\"https://www.fool.com/data-news/2024/11/07/intellia-earnings-beat-revenue-up/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intellia Tops Revenue Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntellia Tops Revenue Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 03:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/data-news/2024/11/07/intellia-earnings-beat-revenue-up/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reported EPS of -$1.34 beat estimates of -$1.39.\n\n\n\n\n\n\n\nRevenue reached $9.1 million, surpassing the $8.28 million analyst estimate.\n\n\n\n\n\n\n\nLead candidates NTLA-2001 and NTLA-2002 achieved significant...</p>\n\n<a href=\"https://www.fool.com/data-news/2024/11/07/intellia-earnings-beat-revenue-up/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4556","symbol_name":"基因编辑","start_time":0,"source_url":"https://www.fool.com/data-news/2024/11/07/intellia-earnings-beat-revenue-up/","article_id":"2481915612","we_media_id":null,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fcdn.content.foolcdn.com%2Fimages%2F1umn9qeh%2Fproduction%2Ff9e7d5f633be79b4ec54a7c055896a8bd6600a6e-600x400.jpg&op=resize&w=165&h=104"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481915612","pubTimestamp":1731007920,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Intellia Therapeutics reported better-than-expected third-quarter earnings, highlighting advancements in its CRISPR gene-editing technology.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4556":"基因编辑","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4588":"碎股","CRSP":"CRISPR Therapeutics AG","LU1861558580.USD":"日兴方舟颠覆性创新基金B"},"translate_title":"Intellia收入超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":0.74},"content_text":"Reported EPS of -$1.34 beat estimates of -$1.39.\n\n\n\n\n\n\n\nRevenue reached $9.1 million, surpassing the $8.28 million analyst estimate.\n\n\n\n\n\n\n\nLead candidates NTLA-2001 and NTLA-2002 achieved significant clinical milestones.\n\nIntellia Therapeutics (NTLA -0.12%), a biotech company specializing in CRISPR gene-editing technology, released its third-quarter 2024 results on November 7, highlighting stronger earnings than expected. The company reported an EPS of -$1.34, better than the forecast -$1.39. Total revenue stood at $9.1 million, exceeding the $8.28 million analyst estimate, boosted by robust collaboration revenue. This quarter underscored Intellia's strides in clinical advancements and strategic partnerships, although financial losses persist.MetricQ3 2024 ResultsAnalyst EstimateQ3 2023 Results% Change Year-on-YearEPS-$1.34-$1.39-$1.404.3%Total Revenue$9.1 million$8.28 million$12.0 million-24.2%R&D Expenses$123.4 millionNot Available$113.7 million8.5%G&A Expenses$30.5 millionNot Available$29.4 million3.7%Source: Analyst estimates for the quarter provided by FactSet.Intellia Therapeutics: An OverviewFounded on groundbreaking CRISPR/Cas9 technology, Intellia Therapeutics works on gene-editing therapies for severe diseases. This technology allows precise DNA modifications, potentially curing genetic conditions. Intellia’s standout programs, NTLA-2001 and NTLA-2002, underscore its pioneering efforts in the biotech sector. Recent endeavors are directed at enhancing therapeutic applications—expanding beyond liver diseases—through this proprietary platform.Currently, Intellia's advancements are fueled by strategic collaborations and regulatory strides, reinforcing its position in genetic medicine. Its partnerships with industry heavyweights like Regeneron (REGN 1.52%) have accelerated development timelines and distributed financial risks.Quarterly InsightsThis quarter was pivotal for Intellia with NTLA-2001 advancing ahead of schedule in the Phase 3 MAGNITUDE trial for ATTR amyloidosis. This expedited enrollment highlights the clinical community's interest in this treatment's potential. Additionally, the U.S. Food and Drug Administration’s (FDA) clearance of the NTLA-2002 IND—indicative of promising HAE Phase 2 results—marks essential regulatory success. NTLA-2002 continues in the Phase 3 HAELO study, further cementing Intellia's clinical pipeline progress.Despite ongoing financial losses of $135.7 million, the company's cash reserves of $945 million ensure operations are funded through late 2026, emphasizing a solid financial position. R&D investments rose from $113.7 million to $123.4 million year-on-year, reflecting intensive program developments. The decline in collaboration revenue from $12.0 million to $9.1 million was offset by progress milestones achieved earlier than expected.Looking AheadLooking forward, Intellia maintains a positive outlook towards potential commercialization phases for NTLA-2001 and NTLA-2002. Investors should monitor the company's continued focus on clinical trial progress and regulatory developments. Watch for updates on cash flow management, given the reliance on external financing for operations.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481915612"}